Results 21 to 30 of about 105,478 (251)

Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles

Drug Delivery, 2020
Esophageal cancer is the sixth most common cause of cancer-related death worldwide. Peptide modified nanoparticles have been engineered as novel strategies to improve esophageal adenocarcinoma (EAC) therapy. This study aimed to develop a trastuzumab (TAB)
Qingxia Fu, Jiancheng Wang, Hong Liu
doaj   +1 more source

MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer

Molecular Therapy: Oncolytics, 2021
Advanced pancreatic cancer is characterized by few treatment options and poor outcomes. Oncolytic virotherapy and chemotherapy involve complementary pharmacodynamics and could synergize to improve therapeutic efficacy.
Hans Martin Singh, Mathias Felix Leber, Sascha Bossow, Christine E. Engeland, Jan Dessila, Christian Grossardt, Karim Zaoui, John C. Bell, Dirk Jäger, Christof von Kalle, Guy Ungerechts   +10 more
doaj   +1 more source

Transient Receptor Potential Cation Channel Subfamily V Member 1 Expression Promotes Chemoresistance in Non-Small-Cell Lung Cancer

Frontiers in Oncology, 2022
Approximately 85% of lung cancer cases are non-small-cell lung cancer (NSCLC). Chemoresistance is a leading cause of chemotherapy failure in NSCLC treatment.
Li Li, Cheng Chen, Qin Xiang, Songqing Fan, Tian Xiao, Yangchao Chen, Duo Zheng   +6 more
doaj   +1 more source

Modified bi‐weekly cetuximab‐cisplatin and 5‐FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients

Cancer Reports, 2022
Background The standard chemotherapy treatment protocol for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) requires as long as 56 days of hospitalization over six months. Where the 5‐Fluorouracil (5‐FU) pump is available,
Amichay Meirovitz, Shani Bergerson, Nir Hirshoren, Jeffrey M. Weinberger, Evgeniya Bersudski, Sharon Daniel, Kim Sheva, Cesar A. Perez   +7 more
doaj   +1 more source

Chondrosarcoma of Ureter in an Elderly Patient: A Case Report

Medicina, 2023
Chondrosarcoma is a rare type of cancer that can affect the upper urinary tract. Because of its rarity, the clinical presentation of chondrosarcoma can be similar to other urinary tract conditions, such as renal colic, hematuria, and urothelial carcinoma.
Szu-Ying Pan, Chien-Zhi Lai, Wen-Chi Chen, Yung-Hsiang Chen, Che-Hung Lin, Han Chang, Chi-Ping Huang, Ching-Chung Yeh   +7 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Dynamic Hydrogels Based on Double Imine Connections and Application for Delivery of Fluorouracil

Frontiers in Chemistry, 2020
Dynamic hydrogels have been prepared by cross-linking of O-carboxymethyl chitosan (O-CMCS) with reversibly connected imino-PEGylated dynamers. The double imine chitosan/dynamer and dynamer bonds and were used to provide tighter structures and adaptive ...
Yan Zhang, Chi-Yen Pham, Rui Yu, Eddy Petit, Suming Li, Mihail Barboiu   +5 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Experimental Study Evaluating the Effect of Combined Methotrexate and Fluorouracil Therapy on Anemia in Mice With L1210 Lymphoid Leukemia

Pteridines, 1997
Combined methotrexate (MTX) and fluorouracil (FU) has heen used for many years to treat neoplastic diseases. However, clinical and laboratory snldies are still carried out to explain the changes that the therapeutic and toxic effects undergo when MTX and
Graczyk Julita
doaj   +1 more source